Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL8676368 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL2810416 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL9365266 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL299439 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL15347870 | 0.98 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL6274726 | 0.95 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676315 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL5014419 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL13938058 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676311 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576203-B2 | Method for producing cyclic diamine derivative | KOWA CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | KOWA CO., LTD (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1767527-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE | Kowa Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-0807627-B1 | Anilide compounds as ACAT inhibitors | KOWA CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | SHIBUYA KIMIYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6204278-B1 | Anilide compounds, including use thereof in ACAT inhibitition | KOWA COMPANY, LTD. (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-0807627-A2 | Anilide compounds as ACAT inhibitors | Kowa Company Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | ACAT1, LCAT, SOAT1 | LMNA 4719/4885GPR84 1518/4885CA1 3276/4885 |
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | SAT1, ACAT2, NAT1 | LMNA 3999/4885GPR84 4356/4885CA1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.